May 4, 2026 Sweden
Diamyd Medical’s new CEO and company founder Anders Essen-Möller outlines next steps, including ongoing evaluations of partnerships and future development plans. Read the article here
|
April 27, 2026 Sweden
Diamyd Medical’s CEO Anders Essen-Möller, comments on the company’s updates. Viewers are welcome to submit questions via the chat.
|
April 16, 2026 Sweden
Diamyd Medical’s CEO Ulf Hannelius answers viewers' question on the strategic alternatives now being evaluated for the company's future.
Produced in collaboration with Biostock and moderated by Cecilia Hallström. Read the article/watch video here
|
March 30, 2026 Sweden
Maria Karlsson Osipova - analyst at DNB Carnegie, interviews Diamyd Medical CEO Ulf Hannelius and board member Mark Atkinson, and Joshua Vieth, BreakthroughT1D, following the DIAGNODE-3 interim readout.
|
March 30, 2026 Sweden
Diamyd Medical’s CEO Ulf Hannelius and board member, Professor Mark Atkinson, comment on the negative interim readout from the ongoing Phase 3 study DIAGNODE-3, announced on March 27, 2026. Read the article here
|